bluebird bio announces further advances in gene therapy for patients with ALD
ALD-104 is now open for enrolment! More information on this clinical study can be found at https://clinicaltrials.gov/ct2/show/NCT03852498?term=bluebird+bio&rank=6.
ALD-104 is an open-label, single-arm, multi-centre study aimed at evaluating safety and efficacy of bluebird bio’s investigational gene therapy after myeloablative conditioning using busulfan and fludarabine in paediatric patients with cerebral adrenoleukodystrophy (CALD).